The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, described as a step towards stronger regulatory understanding and practical support for developers in one of the country's fastest-growing medtech areas.
Published on the MHRA's official blog, the announcement sets out a coordinated effort to help innovators interpret regulatory expectations, improve compliance and bring safe, effective digital mental health products into clinical use. The agency said the initiative responds to rising demand for clarity on evidence requirements, post-market responsibilities and the changing regulatory landscape for software-based and AI-enabled mental health tools.
A forum for shared learning
The community is intended to bring together developers, clinicians, researchers, commissioners and regulatory specialists to build a shared understanding of best practice. The MHRA linked the move to the expansion of the category, which runs from therapeutic apps to AI-supported assessment tools, and to the resulting need for consistent, practical guidance.
The stated objectives are to:
- support developers in interpreting regulatory requirements and embedding compliance earlier in product design;
- identify challenges common to innovators, particularly small and medium-sized enterprises entering the mental health space;
- share real-world experience from organisations already working through regulatory pathways;
- strengthen dialogue between industry and regulators so that emerging technologies meet safety, performance and evidence expectations.
Survey open to developers
To shape the community's initial priorities, the MHRA has opened a survey for digital mental health technology developers and other stakeholders. It explores current regulatory challenges, the areas where clearer guidance is needed and ways to improve compliance support. The agency said broad participation would help the community reflect real-world needs rather than top-down assumptions.
The MHRA is encouraging developers to complete the survey and share it within their organisations, stating that a strong response will help the community deliver support that speeds safe, effective innovation for patients.